The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

Wenyu Hu,1,* Lei Wang,1,* JiaLing Luo,1 Jian Zhang,2 Nanlin Li1 1Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Military Medical University, Xi’an, Shaanxi, People’s Republic of China; 2The State Key Laboratory of Cancer Biology, Department of Biochemi...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Hu W, Wang L, Luo J, Zhang J, Li N
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Dove Medical Press 2023-12-01
Saila:Breast Cancer: Targets and Therapy
Gaiak:
breast cancer
endocrine therapy
cdk inhibitors
apoptosis
abemaciclib
Sarrera elektronikoa:https://www.dovepress.com/the-potent-novel-cdk46-inhibitor-tqb3616-in-hormone-receptor-positive--peer-reviewed-fulltext-article-BCTT

Internet

https://www.dovepress.com/the-potent-novel-cdk46-inhibitor-tqb3616-in-hormone-receptor-positive--peer-reviewed-fulltext-article-BCTT

Antzeko izenburuak